Skip to main content Skip to main navigation menu Skip to site footer

Analysis of Serum Vitamin D Level in Leprosy Patients

  • Nadia Inasya Mozart Darus ,
  • Ramona Dumasari Lubis ,
  • Nelva Karmila Jusuf ,


Introduction: Leprosy is a chronic granulomatous infection with a variety of clinical spectrum caused by Mycobacterium leprae (M. leprae) that is highly influenced by host immune response. In leprosy, vitamin D acts as an immunomodulator through a VDR-mediated antimicrobial pathway that affects the innate immune system to bacterial killing. M. leprae inhibits VDR activity through the down-regulation of CYP27B1. Elevated 1.25(OH)2D levels are required to modulate cathelicidin antimicrobial peptide (CAMP) production, which leads to reduced 25(OH)D level. This study aimed to analyze the difference in serum vitamin D level between leprosy patients and healthy people.

Methods: This research was an analytical observational study with a cross-sectional design involving 20 patients with new cases of leprosy and 20 controls. The diagnosis of leprosy was confirmed through physical examination and laboratory examination. We conducted blood sampling and measurement of serum vitamin D (25(OH)D) level in both groups using the chemiluminescence immunoassay (CLIA) method. The collected data were then processed and analyzed statistically using the Mann-Whitney test.

Result: In this study, we found that the mean serum vitamin D level in leprosy patients (22.27 ± 5.418 ng/mL) was lower than controls (33.00 ± 1.913 ng/mL), and the difference was statistically significant (p < 0.05). The mean serum vitamin D level in male leprosy patients (23.69 ± 4.034 ng/mL) was higher than females (16.55 ± 7.081 ng/mL), and was highest in patients aged 36 – 45 years (25.314 ± 2.2945 ng/mL).

Conclusion: Serum vitamin D level was significantly lower in leprosy patients than in controls. Serum vitamin D level in leprosy patients was higher in the male group and was highest in patients aged 36 – 45 years.


  1. Rea TH, Modlin RL. Leprosy. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. (Eds). Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: The McGraw-Hill Companies; 2012. p. 1786 – 96.
  2. Bryceson A, Pfaltzgraff RE. Epidemiology. Mycobacterium leprae. Leprosy. 3th ed. New York: London Churchill Livingstone; 1990. p. 203 – 16.
  3. World Health Organization. Leprosy today. 2016. Downloaded from [cited 2016 May 23rd].
  4. Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia. Data dan Informasi Tahun 2015. 2016. Available from: [cited 2016 May 23rd].
  5. Mishra RS, Kumar J. Classification. In: Hementa Kumark, Bhushan Kumar, et al. IAL Text Book of Leprosy. New Delhi: Jatpee Brothers Medical Publishers. 2010. p. 144 – 51.
  6. Goulart LR, Goulart IM. Leprosy pathogenetic background: a review and lessons from other mycobacterial disease. Arch Dermatol Res. 2009; 301(2): 123 – 37. DOI: 10.1007/s00403-008-0917-3.
  7. Bartley J, Camargo CA. Vitamin D and infection. In: Gombart AF. Vitamin D: oxidative stress, immunity, and aging. United state: CRC press. 2013. p. 323 – 51.
  8. Mandal D, Reja AHH, Biswas N, Bhattacharyya P, Patra PK, Bhattacharya B. Vitamin D receptor expression levels determine the severity and complexity of disease progression among leprosy reaction patients. New Microbes New Infect. 2015; 6: 35 – 9. DOI: 10.1016/j.nmni.2015.04.001.
  9. Passos Vazquez CM, Mendes Netto RS, Ferreira Barbosa KB, Rodrigues de Moura Moura T, de Almeida RP, et al. Micronutrients influencing the immune response in leprosy. Nutr Hosp. 2014; 29(1): 26 – 36. DOI: 10.3305/nh.2014.29.1.6988.
  10. Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function. Nutrients. 2013; 5(7): 2502 – 2521. DOI: 10.3390/nu5072502.
  11. Chun RF, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin D on immune function: lessons learned from genome-wide analysis. Front Physiol. 2014; 5: 151. DOI: 10.3389/fphys.2014.00151.
  12. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. Endocrinol Metab Clin North Am. 2010; 39(2): 243 – 53. DOI: 10.1016/j.ecl.2010.02.002.
  13. Gupta V. Vitamin D: Extra skeletal effects. Hournal of Medication Nutritions and Neutraceuticals. 2012; 1(1): 17 – 26.
  14. Visweswaran RK, Lekha H. Extraskeletal effects and manifestations of vitamin D deficiency. Indian J Endocrinol Metab. 2013; 17(4): 602 – 10. DOI: 10.4103/2230-8210.113750.
  15. Tsiaras WG, Weinstock MA. Factors influencing vitamin D status. Acta Derm Venereol. 2011; 91(2): 115 – 24. DOI: 10.2340/00015555-0980.
  16. Vanchinathan V, Lim HW. A Dermatologist’s perspective on vitamin D. Mayo Clin Proc. 2012; 87(4): 372 – 80. DOI: 10.1016/j.mayocp.2011.12.010.
  17. Youssef DA, Miller CWT, El-Abbassi AM, Cuthcins DC, Cutchins C, et al. Antimicrobial implications of vitamin D. Dermatoendocrinol. 2011; 3(4): 220 – 229. DOI: 10.4161/derm.3.4.15027.
  18. Mangin M, Sinha R, Fincher K. Inflammation and vitamin D: the infection connection. Inflamm Res. 2014; 63(10): 803 – 19. DOI: 10.1007/s00011-014-0755-z.
  19. Hewison M. Vitamin D and immune function: autocrine, paracrine or endocrine?. Scand J Clin Lab Invest Suppl. 2012; 243: 92 – 102. DOI: 10.3109/00365513.2012.682862.

How to Cite

Darus, N. I. M., Lubis, R. D., & Jusuf, N. K. (2019). Analysis of Serum Vitamin D Level in Leprosy Patients. Bali Medical Journal, 8(3).




Search Panel

Nadia Inasya Mozart Darus
Google Scholar
BMJ Journal

Ramona Dumasari Lubis
Google Scholar
BMJ Journal

Nelva Karmila Jusuf
Google Scholar
BMJ Journal